Phase 3
N=87
Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds
Wound of Skin · Wound Heal · Wound Open · Surgical Wound
Bottom Line
View on ClinicalTrials.gov: NCT03452072 ↗Enrolled (actual)
87
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: Number of Participants With Re-epithelialization at 30 Days Post op — 9; 12 participants — p=0.580
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- 0.25% Timolol gel with paraffin gauze dressings (Drug); Vaseline dressing (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Brigham and Women's Hospital
- Primary completion
- Dec 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Re-epithelialization at 30 Days Post op |
9; 12 | 0.580 |
| SECONDARY Cosmetic Outcomes of Open Surgical Wound Healing by Blinded Physician Vancouver Scar Scale Assessment |
8.8; 8.8 | — |
| SECONDARY Study Subject Complete the Patient Scar Assessment Via Visual Analogue Scale |
5.71; 5.97 | — |
| SECONDARY Number of Participants Whose Side Effects Are Associated With 0.25% Topical Timolol for Open Surgical Wounds |
1; 0 | — |
Summary
The use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is currently emerging in the academic literature. The investigators will enroll 114 patients who have their skin cancer surgically removed resulting in open surgical wounds less or equal to 1.5 cm. The objective of this randomized safety study is to determine the safety and efficacy of 0.25% timolol in promoting wound healing in open surgical wounds less or equal to 1.5 cm.
Eligibility Criteria
Inclusion Criteria
- Age greater than 18 years
- Open surgical wound ≤1.5cm
- No hypersensitivity with use of 0.25% timolol gel
Exclusion Criteria
- Age less than 18 years of age
- Open surgical wound >1.5cm
- Pregnant women
- Use of systemic retinoids within 1 month
- Any hypersensitivity with use of 0.25% timolol gel
Data sourced from ClinicalTrials.gov (NCT03452072). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.